Mepolizumab (Nucala) Submission
Are you someone who suffers from chronic rhinosinusitis with nasal polyps (CRSwNP)? Or maybe you know someone who does.
The Therapeutic Goods Administration (TGA) has released for public consultation changes to the medication MEPOLIZUMAB, which is available in a 100 mg injection in 1 mL single-dose prefilled pen Nucala®.
GlaxoSmithKline Australia Pty Ltd has put an application forward for a treatment of rhinosinusitis with nasal polyps to the TGA Pharmaceutical Benefits Advisory Committee (PBAC). This means if accepted, the medication for treating rhinosinusitis with nasal polyps would be listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised by the government.
You may like to answer the following questions in your submission:
- How has your daily life been impacted by CRSwNP?
- How do the symptoms affect you?
- What’s the impact on work/education/family?
You may also like to comment on the current management options for your CRSwNP. The closing date for submissions is 21 September 2022.